Bruce C. Cozadd - Nov 1, 2021 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Role
Chairman & CEO, Director
Signature
By: /s/Paz Dizon, as attorney in fact For: Bruce C Cozadd
Stock symbol
JAZZ
Transactions as of
Nov 1, 2021
Transactions value $
-$429,140
Form type
4
Date filed
11/3/2021, 04:43 PM
Previous filing
Oct 6, 2021
Next filing
Dec 3, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Options Exercise $454K +9.7K +3.11% $46.83 322K Nov 1, 2021 Direct F1
transaction JAZZ Ordinary Shares Sale -$253K -1.89K -0.59% $133.70 320K Nov 1, 2021 Direct F2, F3
transaction JAZZ Ordinary Shares Sale -$261K -1.93K -0.6% $134.78 318K Nov 1, 2021 Direct F2, F4
transaction JAZZ Ordinary Shares Sale -$370K -2.73K -0.86% $135.45 316K Nov 1, 2021 Direct F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JAZZ Non-Qualified Stock Option (right to buy) Options Exercise $0 -9.7K -10.01% $0.00 87.2K Nov 1, 2021 Ordinary Shares 9.7K $46.83 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 Shares sold to pay option price and to satisfy tax obligations arising from the exercise of stock options.
F3 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $133.08 to $134.03. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $134.163 to $135.134. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.181 to $135.94. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F6 This Non-qualified stock option is part of an option granted on August 9, 2012. The ordinary shares subject to this option vested over 4 years from the grant date with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter and were fully vested as of August 9, 2016.